STRS Ohio’s Century Therapeutics IPSC Stock Holding History

STRS Ohio’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,700	Closed	-$13K	–	2001
2022 Q4	$13K	Hold	2,700	–	–	﹤0.01%	1908
2022 Q3	$26K	Hold	2,700	–	–	﹤0.01%	1909
2022 Q2	$22K	Hold	2,700	–	–	﹤0.01%	1954
2022 Q1	$33K	Hold	2,700	–	–	﹤0.01%	1996
2021 Q4	$42K	Hold	2,700	–	–	﹤0.01%	2025
2021 Q3	$67K	Buy	+2,700	New	+$73.1K	﹤0.01%	2017

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio's IPSC Position: Q1 2023 in Review

STRS Ohio sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 2,700 shares — an estimated $13K sold.

STRS Ohio first reported a position in IPSC in Q3 2021 and held it in 6 quarters. The position peaked at $67K in Q3 2021. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

STRS Ohio reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
STRS Ohio sold 2,700 Century Therapeutics shares in Q1 2023, an estimated $13K.
STRS Ohio first reported a position in Century Therapeutics in Q3 2021 and held it in 6 quarters.
STRS Ohio's Century Therapeutics position peaked at $67K in Q3 2021.
63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on STRS Ohio's 13F filing for Q1 2023, filed 27 Apr 2023.